GLS and cancer: A small molecule inhibitor of glutamine transport (gamma-l-glutamyl-p-nitroanilide) is currently being evaluated in clinical trials [19] and GLS has been validated as a therapeutic target in animal models of some cancers [20-22], leading to Phase I trials of the GLS inhibitor (CB-839) (https://www.clinicaltrials.gov/).